Adaptive Biotechnologies (NASDAQ:ADPT) COO Julie Rubinstein Sells 11,881 Shares of Company Stock

Posted by Bonnie Powley on Nov 11th, 2026

Adaptive Biotechnologies Corporation (NASDAQ:ADPT – Get Free Report) COO Julie Rubinstein sold 11,881 shares of Adaptive Biotechnologies stock in a transaction dated Monday, November 9th. The shares were sold at an average price of $30.12, for a total transaction of $357,855.72. Following the completion of the sale, the chief operating officer owned 377,802 shares in the company, valued at approximately $11,379,396.24. This trade represents a 3.05% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Julie Rubinstein also recently made the following trade(s):

On Thursday, November 5th, Julie Rubinstein sold 11,881 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $26.53, for a total transaction of $315,202.93.
On Friday, October 30th, Julie Rubinstein sold 11,881 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $26.73, for a total transaction of $317,579.13.
On Monday, November 2nd, Julie Rubinstein sold 11,881 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $25.47, for a total transaction of $302,609.07.
On Wednesday, October 28th, Julie Rubinstein sold 11,881 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $28.45, for a total transaction of $338,014.45.
On Monday, October 26th, Julie Rubinstein sold 11,881 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $26.04, for a total value of $309,381.24.
On Friday, October 23rd, Julie Rubinstein sold 11,881 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $24.98, for a total value of $296,787.38.
On Monday, October 19th, Julie Rubinstein sold 11,881 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $24.05, for a total value of $285,738.05.
On Wednesday, October 21st, Julie Rubinstein sold 11,881 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $25.41, for a total value of $301,896.21.
On Thursday, October 15th, Julie Rubinstein sold 11,881 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $25.61, for a total value of $304,272.41.
On Tuesday, October 13th, Julie Rubinstein sold 11,881 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $25.50, for a total value of $302,965.50.

Adaptive Biotechnologies Stock Performance

Shares of NASDAQ:ADPT opened at $29.36 on Wednesday. The company has a debt-to-equity ratio of 1.82, a current ratio of 3.97 and a quick ratio of 3.87. The business’s 50 day moving average price is $26.61 and its 200-day moving average price is $19.97. The firm has a market capitalization of $4.75 billion, a PE ratio of -65.24 and a beta of 2.18. Adaptive Biotechnologies Corporation has a 1 year low of $12.00 and a 1 year high of $30.81.

Adaptive Biotechnologies (NASDAQ:ADPT – Get Free Report) last posted its quarterly earnings data on Wednesday, November 4th. The company reported $0.02 EPS for the quarter, beating the consensus estimate of ($0.10) by $0.12. The firm had revenue of $83.90 million during the quarter, compared to the consensus estimate of $71.57 million. Adaptive Biotechnologies had a negative return on equity of 23.95% and a negative net margin of 23.67%. The firm’s revenue was down 10.7% compared to the same quarter last year. During the same period in the prior year, the company earned $0.06 EPS. As a group, equities research analysts expect that Adaptive Biotechnologies Corporation will post -0.34 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages have recently commented on ADPT. Weiss Ratings reiterated a “sell (d-)” rating on shares of Adaptive Biotechnologies in a research report on Thursday, October 15th. TD Cowen upped their price objective on shares of Adaptive Biotechnologies from $28.00 to $32.00 and gave the company a “buy” rating in a research note on Tuesday, October 13th. BTIG Research upped their price objective on shares of Adaptive Biotechnologies from $25.00 to $34.00 and gave the company a “buy” rating in a research note on Tuesday, September 22nd. Piper Sandler increased their price objective on shares of Adaptive Biotechnologies from $20.00 to $27.50 and gave the company an “overweight” rating in a report on Tuesday, August 4th. Finally, National Bank Financial set a $34.00 target price on shares of Adaptive Biotechnologies in a research note on Tuesday, September 22nd. Six analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $30.31.

Check Out Our Latest Report on Adaptive Biotechnologies

Institutional Trading of Adaptive Biotechnologies

Several large investors have recently added to or reduced their stakes in the stock. Edgestream Partners L.P. acquired a new stake in Adaptive Biotechnologies during the third quarter worth about $621,000. HighTower Advisors LLC purchased a new position in Adaptive Biotechnologies during the third quarter worth about $216,000. Virtus Advisers LLC raised its stake in Adaptive Biotechnologies by 16.1% during the third quarter. Virtus Advisers LLC now owns 18,810 shares of the company’s stock worth $544,000 after purchasing an additional 2,613 shares during the period. Russell Investments Group Ltd. boosted its holdings in Adaptive Biotechnologies by 14.0% in the 3rd quarter. Russell Investments Group Ltd. now owns 89,721 shares of the company’s stock valued at $2,593,000 after purchasing an additional 10,999 shares during the last quarter. Finally, Mesirow Financial Investment Management Inc. acquired a new position in Adaptive Biotechnologies in the 3rd quarter valued at about $252,000. 99.17% of the stock is currently owned by hedge funds and other institutional investors.

Adaptive Biotechnologies Company Profile

(Get Free Report)

Adaptive Biotechnologies is a biotechnology company focused on using the human immune system to diagnose and treat disease. Based in Seattle, Washington, the company develops technologies that sequence and analyze immune cells and their receptors, generating data for clinical testing, research and drug development. Its products include immunoSEQ, a platform used by researchers and biopharmaceutical companies to study immune responses, and clonoSEQ, a clinical test that detects and monitors minimal residual disease in certain blood cancers.